- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01321606
Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study
IMpact of PRObiotics for Reducing Infections in VEterans: The IMPROVE Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Reducing infections caused by S. aureus is essential. The knowledge that colonization at a few key body sites such as the nose and the gastrointestinal tract is a prerequisite for infection2 ,3 offers an opportunity for therapeutic intervention. Thirty percent of the population has nasal colonization with S. aureus. In the last few years, decolonization agents such as mupirocin topical ointment and oral antibiotics such as doxycycline and rifampin have been studied for their utility in reducing colonization. However, these options have limitations in that recolonization is common, the impact of these interventions on multiple sites of colonization has not been assessed and resistance develops frequently to any of these, especially the oral antibiotics. Resistance in S. aureus has been designated a public health crisis. Methicillin-resistant S. aureus (MRSA) now accounts for 60% of all S. aureus infections. As an example of the growing crisis in S. aureus resistance, it should be noted that the number of MRSA infections rose from 2000 in 1993 to 368,000 in 2005. MRSA infections pose an even greater health and economic burden on the population than those caused by methicillin-sensitive S. aureus.4-8 S. aureus and MRSA infection trends in the VA health system mirror national trends5 and are associated with considerable morbidity and mortality in Veterans. A treatment that reduces S. aureus and MRSA colonization, without a risk of promoting antibiotic resistance could represent a breakthrough in decolonization therapy. Probiotics may be one such treatment option.
Probiotics are live microorganisms that are available over the counter, widely used as dietary supplements or nutritional foods and represent a low-cost, well tolerated, safe, non-antibiotic based strategy that may have efficacy for decolonization without the attendant risks of promoting antimicrobial resistance.9 Certain probiotics, including Lactobacillus rhamnosus HN001, have demonstrated ability to stimulate systemic immune functions, possibly enhancing the body's ability to eradicate S. aureus in the gastrointestinal tract and at sites remote from the gastrointestinal tract such as the nose.10 ,11 The long-term goal of this research is to identify and test novel interventions for reducing infections caused by resistant bacteria. The investigators propose a Phase II randomized, double-blind, placebo-controlled clinical trial in Veterans to evaluate the efficacy of an oral probiotic, Lactobacillus rhamnosus HN001, for reducing S. aureus colonization. This study will produce data, methods, and tools that have widespread relevance and portability, with the potential to reduce healthcare-associated infections.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- William S. Middleton Memorial Veterans Hospital, Madison, WI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Colonized at nasal or gastrointestinal source by S. aureus including MRSA
- Age 18 years or older
- Able to take oral medications
- Able to provide informed consent
Exclusion Criteria:
Uncontrolled psychiatric illness
- On a decolonization protocol for MRSA (e.g mupirocin, tea tree oil)
- Current involvement in another investigational trial
- Pregnancy
- Persistent diarrhea (> 3 loose stools per day for at least 2 days)
- Active infection with S.aureus or MRSA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: Probiotic
subjects will be given a capsule formulation of a 1x10^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
|
Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10^10 organisms
|
Placebo Comparator: Arm 2: Placebo
Placebo identical to the active product will be given
|
Placebo identical to the active product will be given
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oral L. Rhamnosus HN001 Therapy Compared to Placebo on Gastrointestinal and Extra-gastrointestinal Colonization of S. Aureus.
Time Frame: 4 weeks
|
Participants in the final outcome may be colonized at both GI and Extra-GI sites, thus the total numbers from the outcome cells can be greater than the overall number of participants analyzed.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oral L. Rhamnosus HN001 Therapy Compared With Placebo on Phagocytic Functioning of Polymorphonuclear (PMN) and Monocyte Cells
Time Frame: 4 weeks
|
This outcome is the mean difference in the % of granulocytes that phagocytized E. coli, from blood samples taken at the beginning and end of the trial.
Percent of granulocytes phagocytizing E. coli at baseline is subtracted by percent of granulocytes phagocytizing E. coli at the end of the trial.
The mean and standard error are calculated and reported for each study arm.
This result
|
4 weeks
|
Oral L. Rhamnosus HN001 Therapy Compared With Placebo on Phagocytic Functioning of Polymorphonuclear (PMN) and Monocyte Cells
Time Frame: 4 weeks
|
This outcome is the mean difference in the % of monocytes that phagocytized E. coli, from blood samples taken at the beginning and end of the trial.
Percent of monocytes phagocytizing E. coli at baseline is subtracted by percent of monocytes phagocytizing E. coli at the end of the trial.
The mean and standard error are calculated and reported for each study arm.
|
4 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nasia Safdar, MD PhD, William S. Middleton Memorial Veterans Hospital, Madison, WI
Publications and helpful links
General Publications
- Eggers S, Barker AK, Valentine S, Hess T, Duster M, Safdar N. Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study. BMC Infect Dis. 2018 Mar 14;18(1):129. doi: 10.1186/s12879-018-3028-6.
- Eggers S, Barker A, Valentine S, Hess T, Duster M, Safdar N. Impact of Probiotics for Reducing Infections in Veterans (IMPROVE): Study protocol for a double-blind, randomized controlled trial to reduce carriage of Staphylococcus aureus. Contemp Clin Trials. 2017 Jan;52:39-45. doi: 10.1016/j.cct.2016.11.004. Epub 2016 Nov 9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-010-10S
- OMB 4040-0001 (Other Identifier: University of Wisconsin, Madison)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anti-biotic Resistance
-
AllerganCompletedAnti-biotic ResistanceUnited States, Canada
-
University of Wisconsin, MadisonCompletedAnti-biotic ResistanceUnited States
-
Hadassah Medical OrganizationTel Aviv UniversityUnknownAnti-Biotic Resistance | Klebsiella PneumoniaeIsrael
-
ART Fertility Clinics LLCCompletedAnti-Mullerian Hormone ResistanceUnited Arab Emirates
-
University of North Carolina, GreensboroRecruitingTolerance | Empathy | Literacy | Norm, Social | Resistance Skills | Beliefs About Consequences | Decision Making Skills | Open Mindedness | Active Citizenship | Anti-extremismUnited States
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Isfahan University of Medical SciencesRecruiting
-
Cosmetique Active InternationalCompleted
-
CONRADUnited States Agency for International Development (USAID); Agility Clinical...CompletedContraceptive Usage | Anti-Infective Agents | Anti-Retroviral AgentsDominican Republic, United States
Clinical Trials on Lactobacillus rhamnosus HN001
-
Boston Medical CenterCompleted
-
Duke UniversityCompletedMicrobiomeUnited States
-
Azienda Ospedaliero, Universitaria PisanaCompleted
-
VU University of AmsterdamYoba for Life FoundationUnknownSkin Diseases | Respiratory Tract Infections | DiarrheaUganda
-
VU University of AmsterdamYoba for Life FoundationCompletedSkin Diseases | Respiratory Tract Infections | Diarrhea | Common Cold | Tinea CapitisUganda
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsCompletedAtopic Dermatitis | Atopic Eczema | Infantile EczemaNetherlands
-
Pablo Román LópezCompleted
-
Medical University of WarsawAdamed Pharma S.A.Not yet recruitingAntibiotic-associated DiarrheaPoland
-
Valio LtdUniversity of Virginia; University of Helsinki; Medcare LtdCompletedRespiratory Tract Infections [C08.730]United States
-
Western University, CanadaNational Institute for Medical Research, TanzaniaCompleted